PAN is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical treatment are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in matching teams of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. Treatment and management of PAN requires individualized management, typically including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of PAN in conjunctive multiarterial arthritis. The platform serves a team of internationally authoritative experts in the field of autoimmune and rheumatic immunity in China.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.